Recent developments in connective tissue disease associated pulmonary arterial hypertension
Stefano Rodolfi1,2,3, Voon H Ong1, Christopher P Denton1
1Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, London, UK.
International Journal of Cardiology. Congenital Heart Disease
|December 23, 2024
Summary
Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) management has improved with clinical trial inclusion. Early detection in CTD offers advantages over idiopathic PAH, though complex comorbidities present challenges.
Area of Science:
- Cardiology
- Rheumatology
- Pulmonology
Background:
- Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) has seen treatment advances.
- Pivotal clinical trials have improved drug availability and patient outcomes for CTD-PAH.
Purpose of the Study:
- To review recent developments in the investigation and management of CTD-PAH.
- To highlight the challenges and opportunities in managing CTD-PAH.
Main Methods:
- Review of recent literature on CTD-PAH.
- Analysis of clinical trial data and management strategies.
Main Results:
- CTD-PAH outcomes have improved but face challenges from comorbidities.
- Systemic sclerosis-associated PAH generally has poorer survival than idiopathic PAH.
- CTD offers potential for early screening and detection of PAH.
Conclusions:
- Despite challenges, CTD-PAH management has benefited from research and clinical trials.
- Early detection in CTD patients may improve long-term prognosis.
- Further research is needed to address complex phenotypes and comorbidities.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
150
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
150
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
171
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
171
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K